Orca Bio has shared promising results from a late-stage study of its investigational allogeneic T-cell immunotherapy in ...

The rate of cGVHD-free survival was 78% at 1 year in patients who received Orca-T compared with 38% among patients who ...

BBIL's 50,000-square-foot CGT facility advances its mission to deliver life-saving treatments for haematological malignancies ...

The firm is also shuttering its allogeneic cell therapy platform and has tasked a new CEO to lead the company through a merger.

Orca-T improved 1-year survival without severe graft-vs-host disease compared with standard transplant in the Precision-T ...

The following is a summary of “Improved survival in older patients with myeloid malignancies undergoing haploidentical ...

Former SVP and Franchise Head for US Oncology at Jazz Pharmaceuticals, with established track record for leading a portfolio ...

Bharat Biotech International Limited (BBIL), a pioneer in affordable indigenous vaccine development and manufacturing, ...

Previously reported Phase 1/2 data on WU-CART-007 demonstrated clinically manageable safety and evidence of anti-leukemic activity with an ...

Autolus reported a net loss of $220.7 million for the year ended December 31, 2024, compared to $208.4 million for the same ...

Despite scoring a historic FDA approval last year, Adaptimmune Therapeutics is expressing concerns about its own longevity, cutting preclinical programs and evaluating strategic options. | Despite a ...

Research examines how lectins, oxalates, and phytates in plant foods may impact nutrients and health—balancing benefits ...